414 related articles for article (PubMed ID: 35309285)
1. A Pooled Analysis of Mortality in Patients with COPD Receiving Dual Bronchodilation with and without Additional Inhaled Corticosteroid.
Miravitlles M; Verhamme K; Calverley PMA; Dreher M; Bayer V; Gardev A; de la Hoz A; Wedzicha J; Price D
Int J Chron Obstruct Pulmon Dis; 2022; 17():545-558. PubMed ID: 35309285
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Versus Other Inhaled Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting β
Ferguson GT; Darken P; Ballal S; Siddiqui MK; Singh B; Attri S; Holmgren U; de Nigris E
Adv Ther; 2020 Jun; 37(6):2956-2975. PubMed ID: 32335859
[TBL] [Abstract][Full Text] [Related]
3. Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease (COPD).
Horita N; Goto A; Shibata Y; Ota E; Nakashima K; Nagai K; Kaneko T
Cochrane Database Syst Rev; 2017 Feb; 2(2):CD012066. PubMed ID: 28185242
[TBL] [Abstract][Full Text] [Related]
4. Inhaled corticosteroids with combination inhaled long-acting beta2-agonists and long-acting muscarinic antagonists for chronic obstructive pulmonary disease.
van Geffen WH; Tan DJ; Walters JA; Walters EH
Cochrane Database Syst Rev; 2023 Dec; 12(12):CD011600. PubMed ID: 38054551
[TBL] [Abstract][Full Text] [Related]
5. Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network meta-analysis.
Oba Y; Keeney E; Ghatehorde N; Dias S
Cochrane Database Syst Rev; 2018 Dec; 12(12):CD012620. PubMed ID: 30521694
[TBL] [Abstract][Full Text] [Related]
6. Stepwise management of COPD: What is next after bronchodilation?
Miravitlles M; Matsunaga K; Dreher M
Ther Adv Respir Dis; 2023; 17():17534666231208630. PubMed ID: 37936381
[TBL] [Abstract][Full Text] [Related]
7. Comparative Effectiveness of Long-Acting Beta
Samp JC; Joo MJ; Schumock GT; Calip GS; Pickard AS; Lee TA
Pharmacotherapy; 2017 Apr; 37(4):447-455. PubMed ID: 28226405
[TBL] [Abstract][Full Text] [Related]
8. Overuse of long-acting β
Brunton SA; Hogarth DK
Postgrad Med; 2023 Nov; 135(8):784-802. PubMed ID: 38032494
[TBL] [Abstract][Full Text] [Related]
9. Role of Long-Acting Muscarinic Antagonist/Long-Acting β
Petite SE
Ann Pharmacother; 2017 Aug; 51(8):696-705. PubMed ID: 28410560
[TBL] [Abstract][Full Text] [Related]
10. Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease.
Fukuda N; Horita N; Kaneko A; Goto A; Kaneko T; Ota E; Kew KM
Cochrane Database Syst Rev; 2023 Jun; 6(6):CD012066. PubMed ID: 37276335
[TBL] [Abstract][Full Text] [Related]
11. LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis.
Rodrigo GJ; Price D; Anzueto A; Singh D; Altman P; Bader G; Patalano F; Fogel R; Kostikas K
Int J Chron Obstruct Pulmon Dis; 2017; 12():907-922. PubMed ID: 28360514
[TBL] [Abstract][Full Text] [Related]
12. Current evidence for COPD management with dual long-acting muscarinic antagonist/long-acting β
Skolnik NS; Nguyen TS; Shrestha A; Ray R; Corbridge TC; Brunton SA
Postgrad Med; 2020 Mar; 132(2):198-205. PubMed ID: 31900019
[TBL] [Abstract][Full Text] [Related]
13. EVELUT®: A Real-World, Observational Study Assessing Dyspnoea and Symptom Burden in COPD Patients Switched from LABA/ICS to LAMA/LABA or LAMA/LABA/ICS.
Buhl R; Dreher M; Mattiucci-Guehlke M; Emerson-Stadler R; Eckhardt S; Taube C; Vogelmeier CF
Adv Ther; 2023 Jul; 40(7):3263-3278. PubMed ID: 37256536
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of Treatment With Dual Bronchodilation (LABA/LAMA) Compared With Combination Therapy (LABA/ICS) for Patients With COPD: A Population-Based Study.
Monteagudo M; Nuñez A; Barrecheguren M; Miravitlles M
Arch Bronconeumol; 2022 Oct; 58(10):699-707. PubMed ID: 35618580
[TBL] [Abstract][Full Text] [Related]
15. Comparative Effectiveness of Umeclidinium/Vilanterol versus Inhaled Corticosteroid/Long-Acting β
Czira A; Requena G; Banks V; Wood R; Tritton T; Castillo CM; Yeap J; Wild R; Compton C; Rothnie KJ; Herth F; Quint JK; Ismaila AS
Int J Chron Obstruct Pulmon Dis; 2023; 18():643-659. PubMed ID: 37155496
[TBL] [Abstract][Full Text] [Related]
16. Comparative Effects of LAMA-LABA-ICS vs LAMA-LABA for COPD: Cohort Study in Real-World Clinical Practice.
Suissa S; Dell'Aniello S; Ernst P
Chest; 2020 Apr; 157(4):846-855. PubMed ID: 31759966
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness and Safety of COPD Maintenance Therapy with Tiotropium/Olodaterol versus LABA/ICS in a US Claims Database.
Quint JK; Montonen J; Esposito DB; He X; Koerner L; Wallace L; de la Hoz A; Miravitlles M
Adv Ther; 2021 May; 38(5):2249-2270. PubMed ID: 33721209
[TBL] [Abstract][Full Text] [Related]
18. Triple Inhaler versus Dual Bronchodilator Therapy in COPD: Real-World Effectiveness on Mortality.
Suissa S; Dell'Aniello S; Ernst P
COPD; 2022 Dec; 19(1):1-9. PubMed ID: 34544314
[TBL] [Abstract][Full Text] [Related]
19. Initiation of Triple Therapy with Multiple Inhalers in Chronic Obstructive Pulmonary Disease: An Analysis of Treatment Patterns from a U.S. Retrospective Database Study.
Lane DC; Stemkowski S; Stanford RH; Tao Z
J Manag Care Spec Pharm; 2018 Nov; 24(11):1165-1172. PubMed ID: 30362922
[TBL] [Abstract][Full Text] [Related]
20. A retrospective study to assess clinical characteristics and time to initiation of open-triple therapy among patients with chronic obstructive pulmonary disease, newly established on long-acting mono- or combination therapy.
Mapel D; Laliberté F; Roberts MH; Sama SR; Sundaresan D; Pilon D; Lefebvre P; Duh MS; Patel J
Int J Chron Obstruct Pulmon Dis; 2017; 12():1825-1836. PubMed ID: 28684905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
